Holen Sie sich die Stockscreener-App
1.42
1.43%
0.02
Schlusskurs vom Vortag:
$1.40
Offen:
$1.4
24-Stunden-Volumen:
47,578
Relative Volume:
0.39
Marktkapitalisierung:
$6.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.50M
KGV:
-0.3225
EPS:
-4.4035
Netto-Cashflow:
$-6.14M
1W Leistung:
-1.39%
1M Leistung:
-0.70%
6M Leistung:
-6.58%
1J Leistung:
-63.21%
1-Tages-Spanne:
$1.3901
$1.42
1-Wochen-Bereich:
$1.38
$1.45
52-Wochen-Spanne:
$1.31
$8.34
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Firmenname
Acurx Pharmaceuticals Inc
Sektor
Branche
Telefon
917-533-1469
Adresse
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
1.42 | 6.23M | 0 | -7.50M | -6.14M | -4.4035 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
Acurx (ACXP) Price-Move Recap: Ends Down by 12.73% at $1.44 in the Latest Reading; Key Levels - vinanet.vn
Acurx Pharmaceuticals Receives FDA Conditional Acceptance - TradingView
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - Yahoo Finance
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com Nigeria
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView
Acurx Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 3ZO0 | US00510M2035 - marketscreener.com
Acurx Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | ACXP | US00510M2035 - marketscreener.com
Acurx Pharmaceuticals Q2 Results: EPS misses estimate, losses widen - scanx.trade
Acurx Pharmaceuticals reports Q2 2026 results, advances antibiotic trials, and strengthens patent portfolio. - Pluang
Acurx Q2 2026 earnings: per-share loss narrows as share count rises - TradingKey
Acurx Receives Conditional FDA Acceptance for C. difficile Drug Name - Stock Titan
ACXP|Acurx Pharmaceuticals Inc|Price:1.450|Chg%:+0.010 - TradingKey
ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView
Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
New patents cover Acurx antibiotics targeting DNA Polymerase IIIC - Stock Titan
Acurx and Leiden Researchers Seek 3D Structure to Guide MRSA Antibiotics - Stock Titan
ACXP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ACXP Q1 2026 Earnings: Narrower Net Loss Beats Expectations, Shares Rise 4.76%EPS Consistency Score - vinanet.vn
Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program - TradingView
FDA Provides Further Regulatory Guidance to A - Moomoo
Acurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reduction - Stock Titan
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Continued R&D ExecutionEarnings Stability Report - vinanet.vn
ACXP Q1 2026 Earnings: Narrower-Than-Expected Per-Share Loss Highlights Cost DisciplineSegment Revenue Breakdown - vinanet.vn
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.480|Chg%:-0.060 - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.395|Chg%:-0.085 - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
TradingKey - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Cash Flow - TradingKey
Acurx Pharmaceuticals (ACXP) Income Statement & Earnings - Moomoo
ACXP Q1 2026 Earnings: EPS Beats Estimates Amid Pre-Revenue Period, Stock Declines Moderately - vinanet.vn
Acurx Pharmaceuticals (ACXP) Registration filing Summary - Quartr
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection - Yahoo Finance Singapore
Acurx data: beneficial gut bacteria remain after repeated C. diff. courses - Stock Titan
Price to earnings forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc. (ACXP) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Yahoo Finance
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - AOL.com
Acurx Pharmaceuticals (ACXP) Slides 8.23% as Stock Tests Key Support at $1.38Relative Volume - dars.gov.et
Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - Ad-hoc-news.de
Finanzdaten der Acurx Pharmaceuticals Inc-Aktie (ACXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):